Sep 14, 2026 09:01AM
Sep 14, 2026 09:00AM
Aug 27, 2026 02:00AM
Aug 27, 2026 02:00AM
Aug 4, 2026 04:01PM
Jul 30, 2026 04:02PM
Jul 30, 2026 04:01PM AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND
Jun 8, 2026 02:56AM
Jun 7, 2026 04:45PM
Jun 3, 2026 09:01AM
Jun 3, 2026 09:00AM
May 19, 2026 04:05PM
May 19, 2026 04:05PM
May 4, 2026 09:01AM AMGEN announces $300 million US manufacturing investment
May 4, 2026 09:00AM
Apr 30, 2026 04:01PM
Apr 30, 2026 04:01PM
Apr 22, 2026 04:00PM
Apr 22, 2026 04:00PM
Apr 6, 2026 09:00AM
Apr 6, 2026 09:00AM AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Mar 28, 2026 04:45PM
Mar 4, 2026 04:02PM
Mar 4, 2026 04:01PM
Feb 3, 2026 04:01PM
Jan 6, 2026 09:01AM
Jan 6, 2026 09:00AM
Dec 19, 2025 02:24PM Amgen expands direct-pay program, cuts drug prices up to 80%
Dec 19, 2025 02:23PM
Dec 11, 2025 06:10PM
Dec 11, 2025 06:09PM
Dec 9, 2025 04:02PM
Dec 9, 2025 04:01PM
Nov 19, 2025 04:02PM
Nov 19, 2025 04:01PM FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
Nov 8, 2025 10:15AM
Nov 8, 2025 10:15AM
Nov 4, 2025 04:01PM
Oct 31, 2025 04:01PM
Oct 31, 2025 04:01PM
Oct 31, 2025 09:00AM
Oct 31, 2025 09:00AM AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
Oct 17, 2025 04:00PM
Oct 17, 2025 04:00PM
Oct 6, 2025 09:01AM
Oct 6, 2025 09:00AM
Oct 6, 2025 09:00AM
Oct 2, 2025 09:00AM
Oct 2, 2025 09:00AM LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
Sep 26, 2025 09:00AM

453,170 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All